Back to results
US 2022/0031804 A1Published application
Therapeutic agent of uremia containing alarin as the main ingredient
AssigneeJu Tide Co., Ltd.
InventorJong-Chul KIM
Life of this patent
Estimating the term…
Abstract
Provided is a novel use of alarin derived from a splice variant of galanin-like peptide (GALP) RNA and thus having an amino acid sequence similar to that of galanin, with a therapeutic agent of uremia, and the therapeutic agents of uremia according to the presently claimed subject matter include alarin as the main ingredient.
Claims6
-6. (canceled)
A method of treating uremia comprising administering to a subject in need thereof a pharmaceutical composition comprising alarin as an active ingredient, wherein the alarin is a human-derived alarin trifluoroacetate salt having the amino acid sequence:
- H-Ala-Pro-Ala-His-Arg-Ser-Ser-Thr-Phe-Pro-Lys-Trp-Val-Thr-Lys-Thr-Glu-Arg-Gly-Arg-Gln-Pro-Leu-Arg-Ser-OH-trifluoroacetate salt (SEQ ID NO:
- 1).
Dependencies are inferred from the claim text.